Viracta Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company, announced that President and CEO Mark Rothera will present at the virtual 2023 SVB Securities Global Biopharma Conference on February 14, 2023, at 1:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company, announced that President and CEO Mark Rothera will present at the virtual 2023 SVB Securities Global Biopharma Conference on February 14, 2023, at 1:00 p.m. ET. The presentation will focus on the company's advancements in treating virus-associated cancers.
A live webcast will be available on the Investors section of the Viracta website and archived for 30 days. Viracta's lead product candidate, Nana-val, is an investigational oral therapy currently evaluated in multiple clinical trials, including treatments for EBV-positive lymphoma and nasopharyngeal carcinoma.
Details
News Market Reaction – VIRX
The recorded move for VIRX in the trading session of this news was +0.51%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, is scheduled to present at the virtual 2023 SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 1:00 p.m. ET.
A live webcast of the presentation will be available on the Investors section of the Viracta website under "Events and Webcasts" and archived for 30 days.
About Viracta Therapeutics, Inc.
Viracta is a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Viracta’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Viracta is also pursuing the application of its “Kick and Kill” approach in other virus-related cancers.
For additional information please visit www.viracta.com.
Investor Relations Contact:
Ashleigh Barreto
Head of Investor Relations & Corporate Communications
Viracta Therapeutics, Inc.
abarreto@viracta.com
SOURCE Viracta Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.